The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).
Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.
Researchers within MAD for Cancer recently published new results for the promising STAT3 inhibitor galiellalactone and its effect on prostate cancer
This study shows that the STAT3 inhibitor galiellalactone reduces tumor growth and metastatic spread in an animal model of prostate cancer. The article “The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer” is published in the journal European Urology
